Stoke Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
12analysts covering
FY Revenue (est.)
$31Mnext fiscal year
FY EPS (est.)
-$3.62next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 3 EMPEROR Study Data Readout | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Phase 3 EMPEROR Study Patient Enrollment Quarterly150.0
Cash, Cash Equivalents, and Marketable Securities Quarterly411MTarget: Sufficient to fund operations into 2028
Quarterly Collaboration Revenue Quarterly6.2MTarget: Variable based on partner milestones
Watch Items
- FDA multidisciplinary discussions regarding expedited regulatory pathways for zorevunersenTrigger: FDA feedback requesting additional information or granting expedited reviewAction: Assess impact on the rolling NDA submission timeline and commercial launch readiness
- Phase 3 EMPEROR study clinical data readoutTrigger: Mid-2027 data releaseAction: Evaluate efficacy (percent change in major motor seizure frequency at week 28) and safety profile to support NDA completion
- Initiation of rolling NDA submission for zorevunersenTrigger: First quarter of 2027Action: Monitor submission progress and prepare commercial infrastructure for potential early 2028 launch
Research as of 20 Jun 2026